Premium
Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta‐analysis of randomized controlled trials
Author(s) -
Lee Young Ho,
Bae SangCheol
Publication year - 2016
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.12822
Subject(s) - tofacitinib , tocilizumab , medicine , abatacept , rituximab , rheumatoid arthritis , randomized controlled trial , infliximab , adverse effect , tumor necrosis factor alpha , lymphoma
Aims This study aimed to assess the relative efficacy and safety of biologics and tofacitinib in patients with rheumatoid arthritis ( RA ) showing an inadequate response to tumor necrosis factor ( TNF ) inhibitors. Methods We performed a Bayesian network meta‐analysis to combine the direct and indirect evidence from randomized controlled trials ( RCT s) examining the efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with RA that inadequately responds to TNF inhibitors. Results Four RCT s including 1796 patients met the inclusion criteria. The tocilizumab 8 mg group showed a significantly higher American College of Rheumatology 20% ( ACR 20) response rate than the abatacept and tofacitinib groups. Ranking probability based on surface under the cumulative ranking curve ( SUCRA ) indicated that tocilizumab 8 mg had the highest probability of being the best treatment for achieving the ACR 20 response rate ( SUCRA = 0.9863), followed by rituximab ( SUCRA = 0.6623), abatacept ( SUCRA = 0.5428), tocilizumab 4 mg ( SUCRA = 0.4956), tofacitinib 10 mg ( SUCRA = 0.4715), tofacitinib 5 mg ( SUCRA = 0.3415) and placebo ( SUCRA = 0). In contrast, the safety based on the number of withdrawals due to adverse events did not differ significantly among the treatment options. Conclusions Tocilizumab 8 mg was the second‐line non‐ TNF biologic with the highest performance regarding an early good response based on ACR 20 response rate and acceptable safety profile, followed by rituximab, abatacept and tofacitinib in patients with RA and an inadequate response to anti‐ TNF therapy, and none of these treatments were associated with a significant risk of withdrawal due to adverse events.